Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257841 · ClinicalTrials.gov registry record · NA
Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01257841: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01257841 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01257841, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The original study executed between 2002-2004 was an interventional trial in which 20, healthy, normal-weight female subjects were randomized to a four-day fast plus daily subcutaneous injections of leptin or a four day fast plus daily subcutaneous injections of a placebo. The primary endpoints were gonadotropin pulsatility, TSH secretion and thyroid function, and cortisol secretion. The current study is a secondary analysis focussed on the placebo group which underwent a four-day fast. The study is looking at the effects of fasting on gut-derived hormones and inflammatory markers in healthy, normal-weight women. The hypothesis for this secondary analysis was that four days of fasting would augment levels of orexigenic gut-derived hormones and suppress levels of anorexigenic gut-derived horomones, while suppressing secretion of inflammatory cytokines.
Interventions
- BEHAVIORAL Fasting
- DRUG Leptin administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257841
The ClinicalTrials.gov registry entry for NCT01257841 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fasting is the first listed.
NCT01257841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01257841 about?
NCT01257841 is a clinical study titled "Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects". The original study executed between 2002-2004 was an interventional trial in which 20, healthy, normal-weight female subjects were randomized to a four-day fast plus daily subcutaneous injections of leptin or a four day fast plus daily subcutaneous injections of a placebo. The primary endpoints were...
What is the current status of trial NCT01257841?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2002-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT01257841?
The interventions under investigation include: Fasting (BEHAVIORAL), Leptin administration (DRUG).
Who is sponsoring clinical trial NCT01257841?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.